Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Puma Biotechnology, Inc. (PBYI) is a Biotechnology company based in US with a market capitalization of $436.7M. Revenue declined 0.9% year-over-year and the company generated $41.7M in free cash flow. This page tracks PBYI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 172 employees · IPO Apr 24, 2012

Valuation

Valuation & price

$6.92as of May 17, 2026· -16.2% vs 52w high

11.3

P/E ratio

Latest-FY diluted EPS

3.35

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$8.22$5.65$3.07Jul 25Jan 26Jul 26
$3.0752-week range$8.26
Loading valuation history…

Fundamentals

Key fundamentals

$436.7M

Market cap

-0.9%

Revenue growth (YoY)

74.5%

Gross margin

$41.7M

Free cash flow (USD)

-$69M

Net debt

Net cash position

2.8%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$0$228.4M

Free cash flow by year

20162025

-$149M$41.7M

Gross margin by year

20212025

74.8%74.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 16, 2026Filing

    Annual Meeting Results

  • 8-K eventMay 7, 2026Filing

    Earnings Release

  • Quarterly reportMay 7, 2026Filing

    10-Q Filed

Questions

Frequently asked questions

What is Puma Biotechnology, Inc.'s market cap?

Puma Biotechnology, Inc. (PBYI) has a market capitalization of $436.7M.

What is PBYI's P/E ratio?

PBYI trades at a price-to-earnings ratio of 11.3, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is PBYI's price-to-book (P/B) ratio?

PBYI trades at 3.35 times book value per share.

Are insiders buying PBYI stock?

SEC Form 4 filings show no open-market insider buys at Puma Biotechnology, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.